- Home
- NAGE vs MGNX Comparison
NAGE vs MGNX Comparison
Compare NAGE & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAGE | MGNX |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | United States |
| Employees | 117 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.2M | 220.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | NAGE | MGNX |
|---|---|---|
| Price | $3.03 | $4.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $16.00 | $5.00 |
| AVG Volume (30 Days) | ★ 782.7K | 741.6K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | $16.51 | N/A |
| Revenue Next Year | $14.58 | $3.19 |
| P/E Ratio | $21.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.87 | $1.30 |
| 52 Week High | $10.52 | $5.08 |
Technical Indicators
Market Signals| Indicator | NAGE | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 40.71 | 49.55 |
| Support Level | N/A | $3.81 |
| Resistance Level | $3.60 | $4.58 |
| Average True Range (ATR) | 0.16 | 0.26 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 21.19 | 56.40 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About MGNX MacroGenics Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.